Fiberside Chat: A Model Is Key for Present and Future Understanding of Your Network

 

It may sound simple, but it’s something many telecommunications companies forget when modeling their network: It’s easier to plan if you have a deep understanding of what the current overview looks like.

Too many telcos may not understand exactly where they have fiber, how close or far it is from their potential customers or how much they would have to connect when evaluating a potential merger and acquisition.

“I think most people understand that today, but some of the people just starting out are looking so much at the right now and not really at the future of what they’re going to do,” said Tommy Siniard, Chief Technical Officer at 3-GIS.

Having the data on exactly what your network looks like can also have big benefits, whether it’s reporting to local authorities, dealing with taxes or even showing places where inefficiencies can be cut and costs can be reduced by eliminating redundancies.

“It’s important to keep in mind that this data, from a financial perspective, can be used for both reducing costs and also growing your network and revenue generation,” said Greg Connors, 3-GIS’ Technical Product Manager.

The best way to achieve some of those goals is to make sure there are open lines of communication between the people managing the fiber network and those in the office.

“In order to get the true value of the data from a financial and reporting perspective, it’s important to understand connectivity both from the outside network, between the buildings, inside the buildings, all the way to the intelligent electronics, which is where the circuits ride,” Conors said. “So, understand down to the level where you could say, this is where these circuits are riding through these fibers through this part of the city.

“That’s challenging, but that’s really where you get the most value out of your physical network and logical combined data.”

Be sure to subscribe to our industry publication for the latest news, videos, and podcasts in the Software & Technology Industry.

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More